FDA fast-tracks Snipr Biome's primary candidate
Snipr Biome’s CRISPR treatment of blood infections in cancer patients has been granted special status by the US Food and Drug Administration.
by victor emil kristensen, translated by catherine brett
Just two weeks after the FDA approved the development plans for Snipr Biome’s candidate, SNIPR001, the company now reveals it has been awarded fast-track status.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Snipr Biome chose clinical debut in CRISPR-ready USA
For subscribers
Snipr Biome to send first candidate to clinic
For subscribers
